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Aims Current guidelines recommend implantable cardioverter-deﬁbrillator (ICD) therapy for primary prevention of
sudden cardiac death in patients with the reduced left ventricular function (LVEF ≤30%) not earlier than 40 days
after myocardial infarction (MI). The aim of the prospective Prevention of Sudden Cardiac Death II (PreSCD II) reg-
istry was to investigate the clinical practice of ICD therapy in post-MI patients and to assess the impact on survival.
Methods
and results
10 612 consecutive patients (61+12 years, 76% male) were enrolled 4 weeks or later after MI in 19 cardiac reha-
bilitation centres in Germany from December 2002 to May 2005. All patients with left ventricular ejection fraction
(LVEF) ≤40% (n ¼ 952) together with a randomly selected group of patients with preserved left ventricular function
(n ¼ 1106) were followed for 36 months. Cox proportional hazard models were used to correlate ICD implantation
and survival with baseline characteristics. Of all patients studied, 75.9% were enrolled within 4–8 weeks, 10.7% more
than 1 year after MI. Pre-speciﬁed Group 1 with an LVEF ≤30% consisted of 269 patients (2.5%), Group 2 with LVEF
31–40% of 727 patients (6.9%), and Group 3 with LVEF .40% of 1148 randomly selected patients from the cohort
of 9616 patients with preserved LV function. After 36 months, only 142 patients (6.9%) had received an ICD; 82
(31.7%) of Group 1, 49 (7%) of Group 2, and 11 (1%) in Group 3. The ICD was implanted in 47% of all patients
within 1 year after their index MI. Implantable cardioverter-deﬁbrillator patients were predominantly characterized
by low ejection fraction, but also by several other independent risk factors. Patients who received an ICD had an
adjusted 44% lower mortality (hazard ratio 0.56, 95% conﬁdence intervals 0.32–1.01; P ¼ 0.053) than comparable
patients without ICD therapy. All cause mortality of ICD recipients was signiﬁcantly lower if the ICD was implanted
later than 11 months after acute MI (P , 0.001).
Conclusions The PreSCD II registry demonstrated that the number of patients who develop a low LVEF (≤30%) after acute MI is
small. However, only few patients with guideline-based ICD indication received ICD therapy. All cause mortality was
signiﬁcantly reduced only if the ICD was implanted late (.11 months) after MI.
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Survivors of myocardial infarction (MI) have an increased risk of
sudden cardiac death (SCD), particularly those with reduced left
ventricular function (LVEF ≤35%).
1–3 Randomized trials have
demonstrated that implantation of an implantable cardioverter-
deﬁbrillator (ICD) for secondary as well as primary prevention
of SCD reduces all-cause mortality.
4–9
The most important risk parameter for all-cause mortality—as
well as sudden arrhythmic death—is reduced left ventricular ejec-
tion fraction (LVEF ≤35%).
10,11 In the MADIT II trial, ICD therapy
led to a 31% reduction of all-cause mortality in patients with LVEF
≤30% and remote MI.
7 These ﬁndings are supported by the
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) in
patients with ischaemic- but also non-ischaemic cardiomyopathy
and additional heart failure with LVEF ≤35%.
9,10 The beneﬁt of
ICD therapy increased with time of ICD implantation after the
index MI.
12
Although sudden death mortality was signiﬁcantly reduced in the
DINAMIT trial,
8 ICD implantation within ,40 days after acute MI
did not reduce all-cause mortality. The reason for the importance
of the time interval after MI is still unclear. Therefore, current
guidelines recommend ICD therapy for primary prevention of
SCD in patients with acute MI not earlier than 40 days after
MI.
13–16
Since  two-thirds of patients who survived a MI in Germany
undergo 3–4 weeks of cardiac rehabilitation (CR) in a specialized
inpatient centre,
17 the aim of the prospective Prevention of
Sudden Cardiac Death II (PreSCD II) registry in post-MI patients
was to investigate the clinical characteristics and the selected
therapeutic approach, particularly the practice of ICD implantation,
in patients after MI, and to assess their long-term outcome.
Methods
Study population
Prevention of Sudden Cardiac Death II, a prospective multicentre reg-
istry, enrolled 10 612 patients after survival of an acute MI in 19 CR
centres throughout Germany from December 2002 to May 2005.
All patients had given written informed consent for the follow-up
investigation.
Patients were eligible for enrolment if they had survived an acute MI
with or without revascularization procedures, percutaneous coronary
interventions (PCI) or coronary artery bypass grafting (CABG) more
than 1 month prior to enrolment. Patients were excluded if they
had already received an ICD, if they were scheduled for coronary
artery bypass or valve surgery, or if they were LV assist system
dependent.
Baseline characteristics including patient history and physical status
were determined at enrolment. The ﬁrst follow-up visit was performed
by the patient’s physician 4 months after enrolment into the registry.
Further follow-up visits were scheduled after 8, 12, 24, and 36
months. Follow-up information was censored 3 years after end of
enrolment, 30 June 2008. Occurrence of death and potential ICD
implantation were retrieved from the patient’s physician or hospitals
involved in treatment of the PreSCD II registry patients.
Based on the assessment of LVEF at least 4 weeks after their index
MI by biplane echocardiography at the CR centre, patients were
assigned to three speciﬁed groups (Figure 1). Group 1 comprises 269
patients (2.5%) with LVEF ≤30%, Group 2 of 727 patients (6.9%)
with LVEF between 31 and 40%, and Group 3 of 1148 patients who
were randomly selected from 9616 patients (90.6%) with LVEF
.40% of the initially enrolled patients. For the remaining 8468
patients, only baseline characteristics were assessed without further
follow-up.
At discharge from the CR centre, ICD implantation was discussed
with patients and their caring physicians if they had a guideline-based
indication for ICD therapy. Performed or denied ICD implantation,
together with the reason for refused ICD implantation, was carefully
documented.
Statistical analysis
Statistical analyses of baseline data and ICD therapy
All further analyses were based on the subpopulation of patients with
follow-up information. Arithmetic means, standard deviations, and
absolute and relative frequencies were used for the description of
the total registry population according to LVEF groups and according
to ICD implantation and compared using Cochran–Armitage trend
tests or polynomial contrast tests (LVEF groups) or x
2 or Mann–
Whitney U tests (ICD vs. no ICD). Isolated missing values were
replaced by imputed values that were calculated using a likelihood-
based algorithm. For a comprehensive analysis of the proﬁle of patients
who received an ICD at any time within 36 months of follow-up, mul-
tiple Cox proportional hazard models were applied since some obser-
vations were censored. Starting with a set of candidate baseline
covariates including in particular time from index MI in three classes
as an anticipated potential source of bias (Table 1), model search
was performed by backward selection. For the ﬁnally selected vari-
ables, adjusted hazard ratios (HR) for ICD implantation are reported
along with 95% conﬁdence intervals (CI) and P-values.
Statistical analyses of mortality data in the follow-up
All registry patients with complete baseline information and at least
one complete follow-up visit were analysed by LVEF classes (Groups
1–3) with respect to death from any cause using Kaplan–Meier tech-
niques and log-rank test. Follow-up times started from enrolment. To
evaluate the differences between ICD patients and comparable
non-ICD patients, a Cox proportional hazard model was applied
with ICD implantation as a time-dependent covariate and further time-
independent covariates that were selected backwards from the same
set of candidate baseline covariates as they were used for analysis of
ICD implantations (Table 2). Results are presented as Forest plots
based on estimated HR and their conﬁdence limits. Additionally
reported P-values are derived from Wald coefﬁcient tests.
Three additional analyses were performed: (i) in a pre-speciﬁed
analysis, the ICD effect was studied separately for Group 1 and
Group 2, i.e. a group with sufﬁcient evidence from randomized trials
and a group with potential ICD implant recommendation. We tested
whether the distinction between the ICD effect in Group 1 and
Group 2 signiﬁcantly improved the model by applying a likelihood
ratio test.
(ii) Since recent trial results (DINAMIT,
8 IRIS
18 indicate that ICD
implantation early after acute MI may not be as beneﬁcial as compared
with later ICD implantation, the ICD beneﬁt was studied depending
on the time from MI to ICD implantation in a post hoc analysis.
Because no suggested cut-offs were available from the literature, we
started with a search for informative cut-offs by likelihood-based
optimization of model ﬁt. We only accepted cut-offs that signiﬁcantly
improved model ﬁt. We present the results of the best ﬁtting model. In
this model, the time-dependent covariate is split into three covariate
H. Vo ¨ller et al. 500according to whether the ICD implantation took place up to 3 months,
between 4 and 11 months, or more than 11 months after inclusion to
the registry.
(iii) At the time when the statistical analysis was designed, time from
index MI to inclusion was assumed to be a relevant confounder or effect
modiﬁer. We thus performed a series of sensitivity analyses where we
used different categorizations of time from index MI, performed a
restricted analysis within the subgroup of recent MIs (,8 weeks) and,
in the complete population, tested interaction terms of time from MI
to inclusion and ICD implantation time to study the robustness of the
presented results to changes in the statistical approach.
Data were gathered and managed by a clinical research organization
(IKKF, Munich, Germany), using internet-based electronic case record
forms. All analyses were performed by the independent study statis-
tician using SAS version 9.1.3.
Results
The PreSCD II registry enrolled 10 612 patients within 30 months,
mean age was 61+12 years, 75.8% of all patients were males. Ear-
liest time of enrolment was 4 weeks after index MI, and 77.4% of
the total cohort was enrolled within 8 weeks after MI. However,
10.7% of the patients who also underwent CR for reasons other
than a recent MI had their MI more than 1 year prior to enrolment.
Approximately 90% of all patients had been revascularized by per-
cutaneous coronary intervention (74.3%) and/or coronary artery
bypass grafting (24.7%). The vast majority of patients (n ¼ 9616;
90.6%) had preserved LVEF .40%, whereas 727 patients (6.9%)
had moderately impaired LV function (LVEF 31–40%), and only
269 patients (2.5%) had severely reduced LV function ≤30%
(Figure 1).
Of the 2144 patients in the pre-speciﬁed three groups who
were scheduled for a long-term follow-up, 86 patients (4%) were
either lost to follow-up prior to the ﬁrst follow-up visit 4
months after CR or refused a further follow-up. Therefore, a
total of 2058 patients remained for 36 months long-term
follow-up. These were 259 patients in Group I (LVEF ≤30%),
693 patients in Group 2 (LVEF 31–40%), and 1106 patients in
Group 3 who were randomly selected from patients who had a
more preserved LV function at the time of enrolment. Patients
with low ejection fraction differ substantially from patients with
better ejection fractions. They are more frequently male, older,
have less weight and less recent MIs and are more severely ill in
almost any regard. There was no difference of baseline medical
treatment between the three groups [beta-blockers (94%),
angiotensin-converting enzyme-inhibitors/angiotensin receptor
blocker (93%), or statins 96%)]. Patient follow-up was scheduled
for 36 months after discharge from CR. Baseline characteristics
of the 2058 patients are presented by LVEF groups in Table 1.
Implantable cardioverter-deﬁbrillator
therapy
The clinical characteristics of patients with (n ¼ 142) or without
(n ¼ 1916) ICD therapy are displayed in Table 2. Of the patients
who received an ICD, 82 patients (58%) were in Group 1, 49
patients (34%) in Group 2, and 11patients (8%) in Group 3. Patients
who were enrolled within 8 weeks after their acute index MI had
relatively less ICD implantation rates (5.5%) than those 15% in
patients who were enrolled but had a more remote MI event.
The PreSCD II registry predominantly enrolled patients early
after their index MI, however, in the majority of cases, the ICD
was not implanted within the early phase of MI. Patients enrolled
within 8 weeks after MI received an ICD a mean of 307 days
after acute MI, patients who had a remote MI at the time of enrol-
ment a mean of 249 days after their MI. Of all 142 patients with ICD
implants, 8% received the device within 8 weeks, 32% within 6
months, 47% within 12 months, and 59% within 24 months.
The result of a multivariate analysis of the impact of patient
characteristics on ICD implantation is depicted in Figure 2.
Figure 1 Flow chart of the PreSCD II registry.
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niﬁcant predictors, the physician’s decision to implant an ICD
was primarily inﬂuenced by the severity of left ventricular dysfunc-
tion. Patients in Group 1 had a 31-fold and in Group 2 a 6-fold
probability compared with Group 3 to receive an ICD (P ,
0.001). Other factors favouring ICD implantation were multiple
MI, increased resting heart rate, occurrence of non-sustained
ventricular tachycardia, QRS duration .120 ms, syncope events,
anti-arrhythmic drug treatment (mostly Class III anti-arrhythmic
drugs), and an index MI of more than 1 year prior to enrolment
into the PreSCD II registry. The likelihood of receiving an ICD
was reduced with higher patient age.
All-cause mortality
Forty-one (2.0%) of 2058 patients available for mortality analysis
were censored before Month 36 because of loss-to-follow-up,
...............................................................................................................................................................................
Table 1 Patient characteristics of 2058 patients according to EF subgroups with a 36-months follow-up in the PreSCD II
registry
Group 1 LVEF≤30%
(n 5 259)
Group 2, LVEF 31–40%
(n 5 693)
Group 3, LVEF>40%,
(n 5 1106)
PTrend
Male (%) 208 (80.31) 550 (79.37) 797 (72.06) ,0.001
Age mean+SD (years) 65.2 (11.3) 63.9 (11.4) 60.8 (11.8) ,0.001
BMI
BMI≤25 kg/m
2 (%) 115 (44.4) 245 (35.4) 297 (26.9) ,0.001
BMI.30 kg/m
2 (%) 40 (15.4) 168 (24.2) 272 (24.6) 0.011
Time from index MI
≤8 weeks (%) 134 (51.7) 470 (67.8) 861 (77.9) ,0.001
8 weeks–1 year (%) 63 (24.3) 121 (17.5) 136 (12.3) ,0.001
.1 year (%) 62 (23.9) 102 (14.7) 109 (9.9) ,0.001
Multiple infarctions (%) 58 (22.4) 122 (17.6) 91 (8.23) ,0.001
Revascularization
PCI (%) 153 (59.1) 450 (65.1) 826 (74.7) ,0.001
CABG (%) 119 (46.0) 262 (37.8) 255 (23.1) ,0.001
Patient history during acute MI
Cardiac arrest (%) 16 (6.2) 26 (3.8) 23 (2.1) ,0.001
VT/VF (%) 12 (4.6) 12 (1.7) 14 (1.3) 0.002
Syncope (%) 20 (8.2) 21 (3.2) 23 (2.2) ,0.001
Pacemaker implantation (%) 16 (6.2) 26 (3.8) 17 (1.5) ,0.001
Co-morbidities
Hypertension (%) 192 (74.1) 507 (73.2) 820 (74.1) 0.840
Diabetes mellitus (%) 97 (37.5) 212 (30.6) 268 (24.2) ,0.001
Renal failure (%) 38 (14.7) 69 (10.0) 60 (5.4) ,0.001
LV ejection fraction
Mean LVEF+SD (%) 26.3 (4.0) 37.2 (2.7) 57.9 (8.9) ,0.001
Heart failure
NYHA I/II (%) 165 (63.7) 612 (88.3) 1089 (98.5) ,0.001
NYHA III/IV (%) 94 (36.3) 81 (11.7) 17 (1.5)
ECG
Sinus rhythm (%) 231 (89.2) 647 (93.4) 1074 (97.1) ,0.001
Atrial ﬁbrillation (%) 28 (10.8) 46 (4.6) 32 (2.9) ,0.001
PQ interval. mean+SD (ms) 172.4 (47.6) 156.3 (48.5) 158.2 (36.7) ,0.001
QRS duration .120 ms (%) 66 (26.8) 82 (12.1) 36 (3.3) ,0.001
Left bundle branch block (%) 77 (29.7) 83 (12.0) 32 (2.9) ,0.001
Non-sustained VT (%) 40 (17.5) 73 (12.8) 58 (6.6) ,0.001
Drug therapy
Beta-blocker (%) 240 (92.7) 651 (93.9) 1051 (95.0) 0.110
ACE/ARB (%) 248 (95.8) 664 (95.8) 1009 (91.2) ,0.001
Statins (%) 244 (94.2) 665 (95.7) 1068 (96.6) 0.095
Antiarrhythmic drugs (III) (%) 34 (13.1) 50 (7.2) 33 (3.0) ,0.001
VT/VF, ventricular tachycardia/ventricular ﬁbrillation
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a total observation time of 6353-patient years, 237 patients died (1
per 27 patient years, 11.5% of the follow-up population). Three-
year all-cause mortality estimated from Kaplan–Meier curves was
4.6% in Group 3, 16.4% in Group 2, and 20.2% in Group 1. In
the subgroup of patients with recent MI (enrolment ≤8 weeks),
the corresponding mortalities were 4.4, 15.9, and 22.5%
(Figure 3). In both analyses, group differences were signiﬁcant.
Cox regression modelling identiﬁed seven baseline covariates
for survival. Severely or moderately reduced EF, higher age, low
body mass index (BMI), renal failure, higher New York Heart
Association (NYHA) class, and multiple MI were associated with
an increased mortality (Figure 4).
Patients who received an ICD had a non-signiﬁcant adjusted 44%
reduction (HR 0.56, 95% CI 0.32–1.01; P ¼ 0.053) of all-cause
mortality compared with those with comparable baseline charac-
teristics, but without ICD. Hazard ratio was 0.53 in Group 1 and
0.74 in Group 2. However, the distinction between Group 1 and
Group 2 did not signiﬁcantly improve the preceding model (P ¼
0.542).
The post hoc analysis of date of MI to ICD implantation time
identiﬁed two cut-offs that improved the model signiﬁcantly (P ,
0.001): 90 days and 330 days. These cut-offs separate a time of 3
months of ICD implant after MI which demonstrates a non-
signiﬁcantly higher mortality than comparable patients who did
not receive an ICD (HR 2.1, 95% CI 0.95–4.65; P ¼ 0.068), a
time period of 4–11 months after MI where ICD patients revealed
a non-signiﬁcant moderate reduction of mortality (HR 0.72, 95%
CI 0.29–1.78; P ¼ 0.469), and a subgroup of patients with ICD
implantation more than 11 months after their index MI with a sig-
niﬁcantly reduced mortality (HR 0.14, 95% CI 0.03–0.56; P ¼
0.006; Figure 4). The analysis was robust if the number of covariates
for adjustment was increased, in particular, if time from index MI to
inclusion that was eliminated during the model search procedure
was added again. For sensitivity analysis, the analysis was repeated
in Group 1 only as well as in patients included within 8 weeks only.
The time trend was the same, but due to the smaller number of
ICD implantations and events, the CI were wider than in the analy-
sis of the total follow-up population. There were no signiﬁcant
differences between groups with respect to time trend. If inter-
action terms of time from index MI to inclusion or of LVEF
groups with ICD implantation times were tentatively added to
the model, none of them was found to be signiﬁcant, indicating
that the presented results are robust with respect to changes in
the patient selection or model assumptions.
Discussion
The PreSCD II registry demonstrated three important ﬁndings:
first, the vast majority of the patients sent to CR centres had pre-
served left ventricular function. Only 9.7% of all patients had an
ejection fraction of ,40%. Secondly, ,one-third of patients fulﬁll-
ing the criteria for guideline-based ICD therapy received the device
within 3 years after enrolment. Decision criteria for ICD implan-
tation were in line with current ICD therapy recommendations.
Thirdly, although the rate of ICD implantations was low within
the follow-up of 36 months, a meaningful beneﬁt with regard to
all-cause mortality could only be demonstrated if ICD implantation
was performed relatively late after acute MI, but not early after
acute MI.
The registry included a large cohort of post-MI patients predo-
minantly referred to CR centres within 4–8 weeks after an acute
MI (9512 patients) and additional 1100 patients (10.7% of the total
patient cohort) who were admitted for inpatient CR, although
their index MI occurred more than 1 year prior to CR. Despite
this relatively early enrolment, 68% of the PreSCD II patients
received their ICD more than 6 months after MI. Hence, in this
registry, ICD implantations occurred over a wide range of time
................................................................................
Table 2 Characteristics of patients with and without
ICD implantation
Variable No ICD
(n 5 1916)
ICD
(n 5 142)
P-value
Male, n (%) 1436 (75.0) 119 (83.8) 0.018
Age, mean SD (years) 62.5+11.8 60.3+10.5 0.030
BMI 0.010
,25 kg/m
2 (%) 596 (31.1) 61 (43.0)
≥30 kg/m
2 (%) 456 (23.8) 24 (16.9)
Time from index MI ,0.001
≤8 weeks (%) 1385 (72.3) 80 (56.3)
8 weeks–1 year (%) 299 (15.6) 21 (14.8)
.1 year (%) 232 (12.1) 41 (28.9)
Multiple MI (%) 233 (12.2) 38 (26.8) ,0.001
LV ejection fraction ,0.001
≤30 (%) 177 (9.2) 82 (57.8)
31–40 (%) 644 (33.6) 49 (34.5)
.40 (%) 1095 (57.2) 11 (7.8)
NYHA Class ,0.001
II (%) 737 (38.5) 67 (47.2)
III/IV (%) 147 (7.7) 45 (31.7)
Co-morbidity
Hypertension (%) 1422 (74.2) 97 (68.3) 0.122
Diabetes mellitus (%) 536 (28.0) 41 (28.9) 0.818
Renal failure (%) 148 (7.7) 19 (13.4) 0.017
Syncope (%) 55 (2.9) 14 (9.9) ,0.001
ECG
QRS duration
.120 ms (%)
161 (8.4) 42 (29.6) ,0.001
Atrial ﬁbrillation (%) 97 (5.1) 9 (6.3) 0.507
Non-sustained VT 1707 (9.9) 32 (22.5) ,0.001
Drug therapy
Beta-blocker (%) 1811 (94.5) 131 (92.3) 0.259
ACE/ARB (%) 1785 (93.2) 136 (95.8) 0.228
Statins (%) 1839 (96.0) 138 (97.2) 0.477
Antiarrhythmic
drugs (III) (%)
97 (5.1) 20 (14.1) ,0.001
All values are n (%), if not speciﬁed otherwise. P-values refer to comparison
between the subgroups with or without ICD therapy.
BMI, body mass index; MI, myocardial infarction; NYHA, New York Heart
Association; ECG, electrocardiogram; VT, ventricular tachycardia; ACE,
angiotensin-converting enzyme-inhibitor; ARB, angiotensin receptor blocker.
Time of ICD implantation and impact on mortality 503intervals from study entry as well as from most recent MI, thus
covering a range that links the patients enrolled in the IRIS
18 and
DINAMIT
8 trial with the MADIT-II
7 cohort. The majority of the
patients were enrolled later than those studied in the DINAMIT
or IRIS trial—however, PreSCD II evaluated patients earlier than
in MADIT II since in this trial only 12% of the patients were
recruited within the ﬁrst 6 months post-MI. This way, we can for
the ﬁrst time directly compare these populations in one database
with a sufﬁcient number of patients that ﬁll the gap between the
trials.
Compared with previous studies of patients after acute MI, the
proportion of patients with severely reduced LVEF in the
PreSCD II registry was smaller than expected. During the throm-
bolysis era of MI, 20% of all patients showed severely reduced ven-
tricular function with an LVEF ≤30% after MI. Due to more often
applied coronary revascularization, particularly with acute PCI
more patients survive with preserved ventricular function.
19,20 In
recent studies with primary PCI in acute MI patients revealed a
severely reduced LVEF (,30%) in ,5%.
20,21 Approximately 75%
of the PreSCD II patients had PCI and/or CABG (25%).
Figure 2 Effect of various patient and treatment characteristics on the probability of ICD implantation during 36-month follow-up of 2058
patients (hazard ratios).
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cardioverter-deﬁbrillator therapy
More than two-thirds of high-risk patients (LVEF ≤30%) eligible
for ICD implantation did not receive ICD therapy after risk assess-
ment during CR (Figure 1), although this variable had the greatest
impact on the decision-making process of ICD implantation.
Poor adherence to current ICD guidelines has been reported.
22,23
Several reasons may explain our ﬁndings.
When the PreSCD II registry was started in 2002, 9 months after
the MADIT II results were published, guidelines recommended
ICD implantation as a ‘Class II a’ indication.
13,15 This has changed
since 2005 after the SCD-HeFT and DINAMIT trials had been pub-
lished.
14,16 DINAMIT demonstrated that ICD implantation within
40 days after an acute MI in patients with LVEF ≤35% does not
reduce all-cause mortality, although sudden arrhythmic death
was signiﬁcantly diminished.
8,16 Current recommendations
exclude ICD implantation within this time frame after MI.
16
Post hoc analyses of MADIT II data indicate that the highest ICD
beneﬁt may be achieved in the chronic phase of MI e.g. more
than 18 months after MI.
24 The rate of ICD implantation in the
PreSCD II registry was signiﬁcantly higher in patients with a
remote MI (≥365 days).
Reasons for not implanting an ICD during the follow-up time of
the registry in patients with severely reduced LV function were
assessed. Denial of patients (29.2%) to receive an ICD or reluc-
tance of their physicians to recommend ICD therapy (34.7%)
was the main argument for not implanting an ICD, followed by
patient’s poor physical condition, short-life expectancy and
advanced age (29.2%).
On the contrary, published data demonstrate that particularly
patients with the combination of severely reduced LV function,
older age, and more risk parameters including impaired renal
function have signiﬁcant beneﬁt from ICD therapy.
10,11,25,26
Recent post hoc analyses have shown that post-MI patients with
non-sustained ventricular tachycardia (VT), previous syncope, or
prolonged QRS duration carry a very high risk of SCD.
27–31
With the exception of age, these risk parameters were also used
for decision-making for ICD implantation in PreSCD II. Variables
like multiple MI, QRS duration .120 ms, non-sustained VT, or
syncope doubled the probability of ICD implantation.
Impact on mortality
Risk factors for increased mortality identiﬁed in our registry popu-
lation by backward selection are well in line with observations in
trials and other registries.
3,19,25,26,31–35 While increasing age, a
severely or moderately reduced LVEF, high NYHA class, multiple
MI, a QRS duration .150 ms, and renal failure go along with a
two-fold increased mortality risk, ICD therapy showed a meaning-
fully diminished reduction of all-cause mortality in the registry
cohort.
The overall adjusted HR for ICD therapy in PreSCD II was 0.56,
and 0.53 in the subgroup of patients with LVEF ≤30%. However,
the registry data failed to show a signiﬁcant difference between
patients with or without ICD implantation. A possible explanation
may be the limited amount of ICD observation time due to the low
ICD implantation rate. Although it is tempting to discuss the small
difference between ICD effects in patients with LVEF ≤30% and
LVEF 31–40%, it would be statistically incorrect because of the
limited power of this analysis. The ICD beneﬁt difference,
however, was strong enough to allow a conclusion similar to
those from other ICD trials after MI. According to our analysis,
late ICD implantation ≥11 months after acute MI was beneﬁcial
concerning all-cause mortality, whereas ICD implantation within
the ﬁrst 3 months after MI may even be detrimental. Implantable
cardioverter-deﬁbrillator implantation between 4 and 10 months
after MI did not demonstrate a clear advantage. The time shift in
the beneﬁt of ICD therapy was still present if the analysis was
restricted to patients with LVEF ≤30%, or if other sets of covari-
ates were applied. This robust result from ‘real-life data’ comp-
lements the observations from randomized trials. For the ﬁrst
time, the PreSCD II registry allows an empirical determination of
potential cut-offs from a database that covers a broad range of
possible time points for implantation.
Limitations
Several limitations have to be considered when interpreting the
presented results. Prevention of Sudden Cardiac Death II is a reg-
istry and not a randomized clinical trial. A hidden bias and limited
assessment of covariates may have confounded the comparisons.
Particularly, bias by indication is a potential scenario since we
may have failed to control all criteria which may have inﬂuenced
the decision to implant ICDs. Although more than 10 000
post-MI patients were originally enrolled, the hypothesized
number of  600 patients with severely reduced LV function was
not met, and the ICD implantation rate was less than expected.
This resulted in a reduced power compared with well-accepted
ICD trials. However, the power was sufﬁcient to demonstrate
the effect of known risk parameters and the importance of the
time frame of ICD implantation. Another limitation of the
Figure 3 Kaplan–Meier estimate of all-cause mortality in the
36-months follow-up, divided by LVEF groups, restricted to
recent myocardial infarctions (≤8 weeks at inclusion). The
P-value results from a log-rank test.
Time of ICD implantation and impact on mortality 505PreSCD II registry is the lack of completeness of data acquisition,
particularly the unknown mode of death of the registry patients
during the follow-up time. No information was available about a
potential improvement of left ventricular function during follow-up
which may have inﬂuenced the decision not to implant an ICD.
It needs to be emphasized that the analysis of ICD implantation
time represents a post hoc analysis. The selection of cut-offs had to
be done data driven, resulting in an optimistic bias of unknown size.
The results of our analyses are not solid enough to deduce any
clinically meaningful recommendations concerning ICD implan-
tation.
8,12,17 However, there were no substantial changes of the
results in several sensitivity analyses with different methods of
statistical control of potential sources of bias or within selected
subgroups. Thus, based on our results, it seems justiﬁed to ask
for more evidence on the dependency of the ICD beneﬁt in mor-
tality reduction on device implantation time, in particular, in the
early phase up to 1 year after an acute MI.
Conclusion
The portion of post-MI patients admitted to CR centres with
reduced left ventricular function who are eligible for ICD implan-
tation was low in this registry. Less than one-third of high-risk
post-MI patients received ICD therapy although they were
Figure 4 Effect of various patient and treatment characteristics on mortality during 36-month follow-up of 2058 patients.
H. Vo ¨ller et al. 506recommended in the guidelines for ICD therapy. However, Cox
regression analysis on 3-years follow-up data of the PreSCD II reg-
istry demonstrates that the decision to implement ICD therapy
into clinical practice was based on parameters that have been
associated with a higher risk of all-cause mortality. Within 3
years of follow-up, the overall mortality of all enrolled patients
was non-signiﬁcantly lower with ICD therapy, although in a post
hoc analysis a signiﬁcant reduction of mortality over time could
be observed depending on the time interval between index MI
and ICD implantation.
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